Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 08423: PHASE 2 SINGLE-ARM NON-INFERIORITY STUDY OF LIMITED-DURATION TECLISTAMAB FOR RELAPSED REFRACTORY MULTIPLE MYELOMA

99 years or below
All genders
Phase 2
Please refer to Protocol Section 4 Please refer to Protocol Section 4 Please refer to Protocol Section 4
Learn More

UPCC 18822: Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma

99 years or below
All genders
Please refer to Protocol Section 3.0. Please refer to Protocol Section 3.1. Please refer to Protocol Section 3.2.
Learn More

UPCC 12122 SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibit

99 years or below
All genders
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation
Learn More

UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
Learn More

UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
Learn More

UPCC 53422: An Open-Label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma The Protocol

99 years or below
All genders
Phase 1
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
Learn More

UPCC 29922: First-in-human open-label multicenter Phase I/IIa dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

99 years or below
All genders
Phase 1
Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Objectives and endpoints. Please refer to Protocol BNT142-01, section 1.1 Trial synopsis, Secondary objectives.
Learn More

UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
Learn More

UPCC 18422: A Study of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with High-Risk Translocations

99 years or below
All genders
Phase 2
Please refer to Protocol Section 2.0. Please refer to Protocol Section 12.0 Please refer to Protocol Section 12.0
Learn More

UPCC 08422 A Phase 1b/2 Open-Label Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody -CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richters Syndrome

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
1181 - 1190 of 1243